{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:29:34Z","timestamp":1780072174384,"version":"3.54.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jtho.2020.11.005","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T16:41:22Z","timestamp":1605112882000},"page":"381-394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies"],"prefix":"10.1016","volume":"16","author":[{"given":"Elia","family":"Sechi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2020.11.005_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2020.11.005_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jtho.2020.11.005_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2020.11.005_bib4","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.11.005_bib5","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","article-title":"Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses","volume":"10","author":"Nishimura","year":"1998","journal-title":"Int Immunol"},{"key":"10.1016\/j.jtho.2020.11.005_bib6","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.mayocp.2019.02.003","article-title":"Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy","volume":"94","author":"Zekeridou","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtho.2020.11.005_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy [published correction appears in Front Pharmacol. 2017;8:311]","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtho.2020.11.005_bib8","doi-asserted-by":"crossref","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2020.11.005_bib9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib10","first-page":"881","article-title":"The expression of the Hu (paraneoplastic encephalomyelitis\/sensory neuronopathy) antigen in human normal and tumor tissues","volume":"141","author":"Dalmau","year":"1992","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtho.2020.11.005_bib11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jtho.2020.11.005_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-510X(99)00163-X","article-title":"Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody","volume":"168","author":"Tanaka","year":"1999","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.jtho.2020.11.005_bib13","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/brain\/aww225","article-title":"CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model","volume":"139","author":"Yshii","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.jtho.2020.11.005_bib14","doi-asserted-by":"crossref","first-page":"576980","DOI":"10.1016\/j.jneuroim.2019.576980","article-title":"A\u00a0case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes","volume":"334","author":"Gill","year":"2019","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jtho.2020.11.005_bib15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.24715","article-title":"CTLA4 as immunological checkpoint in the development of multiple sclerosis","volume":"80","author":"Gerdes","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1084\/jem.20022119","article-title":"Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis [published correction appears in J Exp Med. 2003;198:677]","volume":"198","author":"Salama","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtho.2020.11.005_bib17","doi-asserted-by":"crossref","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2020.11.005_bib18","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","article-title":"A\u00a0case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis","volume":"25","author":"Johnson","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2020.11.005_bib19","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.11.005_bib20","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy [published correction appears in N Engl J Med. 2018;379:2185]","volume":"375","author":"Eggermont","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.11.005_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.11.005_bib22","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.11.005_bib23","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis [published correction appears in JAMA Oncol. 2018;4:1792]","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2020.11.005_bib24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/1759-7714.13009","article-title":"Paraneoplastic autoimmunity and small-cell lung cancer: neurological and serological accompaniments","volume":"10","author":"Zekeridou","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2020.11.005_bib25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaneurol.2016.0603","article-title":"Frequency of synaptic autoantibody accompaniments and neurological manifestations of thymoma","volume":"73","author":"Zekeridou","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1212\/WNL.0000000000001721","article-title":"Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study","volume":"85","author":"Gozzard","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2020.11.005_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143558","article-title":"Novel humoral prognostic markers in small-cell lung carcinoma: a prospective study","volume":"10","author":"Gozzard","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2020.11.005_bib28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/mus.23774","article-title":"Striational antibodies in a paraneoplastic context","volume":"47","author":"McKeon","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jtho.2020.11.005_bib29","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2020.11.005_bib30","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2020.11.005_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2020.11.005_bib32","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.jtho.2020.11.005_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/rheumatology\/kez235","article-title":"ANCA-associated vasculitic neuropathy during treatment with ipilimumab","volume":"59","author":"Villarreal-Compagny","year":"2020","journal-title":"Rheumatology (Oxford.)"},{"key":"10.1016\/j.jtho.2020.11.005_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40425-018-0396-9","article-title":"Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report","volume":"6","author":"Appelbaum","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2020.11.005_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.mayocpiqo.2017.07.004","article-title":"Brachial plexus neuritis associated with anti-programmed cell death-1 antibodies: report of 2 cases","volume":"1","author":"Alhammad","year":"2017","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.jtho.2020.11.005_bib36","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with antiprogrammed death 1 (PD-1) antibodies [published correction appears in JAMA Neurol. 2017;74:1271]","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"137","author":"Fellner","year":"2018","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.jtho.2020.11.005_bib38","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2020.11.005_bib40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.2019-0508","article-title":"Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a review of literature","volume":"25","author":"Chan","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2020.11.005_bib41","first-page":"208","article-title":"PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jtho.2020.11.005_bib42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000494078","article-title":"Lambert\u2013Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer","volume":"10","author":"Nakatani","year":"2018","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib43","first-page":"e985","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer [published correction appears in Neurology. 2019;93:280]","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2020.11.005_bib44","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2020.11.005_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2020.11.005_bib46","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib47","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1212\/WNL.0000000000007971","article-title":"Phosphodiesterase 10A IgG: a novel biomarker of paraneoplastic neurologic autoimmunity","volume":"93","author":"Zekeridou","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2020.11.005_bib48","doi-asserted-by":"crossref","first-page":"e1677","DOI":"10.1212\/WNL.0000000000006435","article-title":"Paraneoplastic neuronal intermediate filament autoimmunity","volume":"91","author":"Basal","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2020.11.005_bib49","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1212\/NXI.0000000000000604","article-title":"Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors","volume":"6","author":"Vogrig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jtho.2020.11.005_bib50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11940-019-0550-9","article-title":"Diagnosis and management of autoimmune dementia","volume":"21","author":"Sechi","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2019.4379","article-title":"CRMP5-IgG-associated paraneoplastic myelopathy with PD-L1 inhibitor therapy","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib52","first-page":"282","article-title":"Susac\u2019s syndrome as an immune-related adverse event after pembrolizumab: a case report","volume":"267","author":"De Groot","year":"2020","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40425-017-0249-y","article-title":"Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade","volume":"5","author":"L\u00e4ubli","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2020.11.005_bib54","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000362614","article-title":"New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment","volume":"37","author":"Murphy","year":"2014","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.jtho.2020.11.005_bib55","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1200\/JCO.2011.38.7886","article-title":"Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma","volume":"30","author":"Maur","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.11.005_bib56","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2326-6066.CIR-15-0035","article-title":"Ipilimumab-induced encephalopathy with a reversible splenial lesion","volume":"3","author":"Conry","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2020.11.005_bib57","first-page":"80","article-title":"Vogt\u2013Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma","volume":"38","author":"Crosson","year":"2015","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jtho.2020.11.005_bib58","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/2326-6066.CIR-15-0141","article-title":"Subacute CNS demyelination after treatment with nivolumab for melanoma","volume":"3","author":"Maurice","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2020.11.005_bib59","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s40425-019-0818-3","article-title":"Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient","volume":"7","author":"Pillonel","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2020.11.005_bib60","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jtho.2020.11.005_bib61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12885-018-3997-2","article-title":"Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report","volume":"18","author":"Narumi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2020.11.005_bib62","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2020.11.005_bib63","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1001\/archneur.57.12.1727","article-title":"Altered mental status in patients with cancer","volume":"57","author":"Tuma","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2020.11.005_bib65","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors","volume":"91","author":"Vogrig","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jtho.2020.11.005_bib66","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtho.2020.11.005_bib67","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.10178","article-title":"Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma","volume":"51","author":"Vernino","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib68","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.mayocp.2018.01.001","article-title":"Multiple cranial neuropathies from nivolumab in a patient with metastatic hepatocellular carcinoma","volume":"93","author":"Siegel","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtho.2020.11.005_bib69","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtho.2020.11.005_bib70","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1212\/WNL.0b013e31821f468f","article-title":"Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues","volume":"76","author":"Flanagan","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2020.11.005_bib71","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WNP.0b013e31821c33a0","article-title":"EEG patterns and imaging correlations in encephalopathy: encephalopathy part II","volume":"28","author":"Kaplan","year":"2011","journal-title":"J\u00a0Clin Neurophysiol"},{"key":"10.1016\/j.jtho.2020.11.005_bib72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2020.11.005_bib73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"suppl 4","key":"10.1016\/j.jtho.2020.11.005_bib74","doi-asserted-by":"crossref","first-page":"iv100","DOI":"10.1093\/annonc\/mdx216","article-title":"Management of infusion reactions to systemic anticancer therapy: ESMO clinical practice guidelines","volume":"28","author":"Rosell\u00f3","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.11.005_bib75","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40425-018-0480-1","article-title":"Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis","volume":"6","author":"Esfahani","year":"2018","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420310273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420310273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:45:06Z","timestamp":1761561906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086420310273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1556086420310273"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2020.11.005","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2020.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}